Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.62%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.53%AUDUSD-1.44%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.81%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.68%CADJPY-0.66%NZDJPY-0.65%USDCHF+0.63%GBPUSD-0.62%USDCAD+0.58%EURUSD-0.58%NZDUSD-0.54%AUDSGD-0.51%AUDDKK-0.43%USDZAR+0.42%GBPTRY+0.41%NZDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%USDMXN+0.31%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.25%USDTRY+0.21%USDSEK+0.20%USDPLN+0.19%CHFNOK+0.18%EURCNH-0.17%USDILS+0.16%NOKJPY-0.15%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.12%USDCNH-0.12%USDJPY-0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.08%GBPNZD-0.07%PLNJPY-0.07%EURSEK+0.06%SGDJPY+0.06%USDSGD+0.06%GBPCAD-0.06%NZDCHF+0.05%EURGBP+0.05%EURPLN+0.05%EURCHF+0.05%USDCOP-0.04%CADCHF+0.04%EURNZD-0.04%EURCZK+0.04%CHFSGD-0.02%NZDCAD+0.01%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.75%XPTUSD-0.73%W1-0.51%C1-0.41%XAUUSD-0.30%GAUUSD-0.29%HG1-0.23%GAGUSD-0.22%UKOIL+0.21%XAGUSD-0.21%S1-0.17%COTTON+0.10%BTCUSD-2.91%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-5.93%XMRUSDT-1.68%DOGEUSD+55.95%LINKUSD-2.70%XLMUSD-3.12%BCHUSDT-3.08%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.16%TONUSD+59.18%HBARUSDT-4.75%TAOUSDT-2.34%AAVEUSD-2.66%ONDOUSDT-4.17%ICPUSDT-1.39%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.23%ATOMUSDT-1.79%INJUSDT-6.62%STXUSDT-1.86%PYTHUSDT+0.43%TIAUSDT-2.26%FETUSDT-3.90%JUPUSDT+1.01%SEIUSDT-2.00%GRTUSDT-2.83%OPUSDT-2.63%IOTAUSDT-1.99%POLUSDT-1.48%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-5.97%GALAUSDT-1.65%DYDXUSDT-2.23%ORDIUSDT-1.75%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.62%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.53%AUDUSD-1.44%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.81%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.68%CADJPY-0.66%NZDJPY-0.65%USDCHF+0.63%GBPUSD-0.62%USDCAD+0.58%EURUSD-0.58%NZDUSD-0.54%AUDSGD-0.51%AUDDKK-0.43%USDZAR+0.42%GBPTRY+0.41%NZDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%USDMXN+0.31%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.25%USDTRY+0.21%USDSEK+0.20%USDPLN+0.19%CHFNOK+0.18%EURCNH-0.17%USDILS+0.16%NOKJPY-0.15%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.12%USDCNH-0.12%USDJPY-0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.08%GBPNZD-0.07%PLNJPY-0.07%EURSEK+0.06%SGDJPY+0.06%USDSGD+0.06%GBPCAD-0.06%NZDCHF+0.05%EURGBP+0.05%EURPLN+0.05%EURCHF+0.05%USDCOP-0.04%CADCHF+0.04%EURNZD-0.04%EURCZK+0.04%CHFSGD-0.02%NZDCAD+0.01%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.75%XPTUSD-0.73%W1-0.51%C1-0.41%XAUUSD-0.30%GAUUSD-0.29%HG1-0.23%GAGUSD-0.22%UKOIL+0.21%XAGUSD-0.21%S1-0.17%COTTON+0.10%BTCUSD-2.91%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-5.93%XMRUSDT-1.68%DOGEUSD+55.95%LINKUSD-2.70%XLMUSD-3.12%BCHUSDT-3.08%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.16%TONUSD+59.18%HBARUSDT-4.75%TAOUSDT-2.34%AAVEUSD-2.66%ONDOUSDT-4.17%ICPUSDT-1.39%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.23%ATOMUSDT-1.79%INJUSDT-6.62%STXUSDT-1.86%PYTHUSDT+0.43%TIAUSDT-2.26%FETUSDT-3.90%JUPUSDT+1.01%SEIUSDT-2.00%GRTUSDT-2.83%OPUSDT-2.63%IOTAUSDT-1.99%POLUSDT-1.48%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-5.97%GALAUSDT-1.65%DYDXUSDT-2.23%ORDIUSDT-1.75%NOTUSDT-0.74%RONINUSDT-2.92%
BT

Beam Therapeutics Inc. (BEAM)

NASDAQ • Healthcare

$21.01
+$0.36 (+1.7%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$20.76
Day Range$20.66 - $22.4
Avg. Volume (3M)2.2M
Market Cap$2.1B
52 Week Range
$20.23$38.26

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$307K100%
Gross Profitminus cost of goods$307K100%

Fundamentals & Financials

Revenue (TTM)
$146.6M
Net Income (TTM)
-$107.1M
EPS (TTM)
-$1
ROA (TTM)
-8.44%
Current Ratio
13

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.6%Q2 2026-$0.91
-6.3%Q3 2026-$1.18
-11.3%Q4 2026-$1.28

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -11.3%

Beam Therapeutics’ EPS trailed consensus in the third fiscal quarter of 2026, reported November 3, 2026, with EPS of -$1.28 trailing the -$1.15 estimate by -$0.13 and deteriorating from -$1.10 a year ago (a -16.4% year-over-year change). The quarter’s net loss widened as net income fell 19.2% year over year to roughly -$134.4 million (down from -$112.7 million a year ago), alongside an operating loss of about -$141.3 million, as the company continued investing across its gene-editing pipeline programs including BEAM-101, BEAM-102, BEAM-201, and BEAM-301. Cash generation remained negative, with negative operating cash flow of around -$110.7 million. For the next period, consensus calls for EPS of -$1.25 on revenue of $7.9 million.

View full earnings history

About Beam Therapeutics Inc.

Beam Therapeutics Inc. develops gene-editing medicines in biotechnology, focused on precise genetic remedies for severe diseases. The company, which trades on NASDAQ as BEAM, recorded $139.7 million in revenue in FY2025. Its work centers on engineered therapies for blood disorders and other serious conditions, with operations based in the United States.

Name
Beam Therapeutics Inc.
CEO
John Evans
Industry
Healthcare
Year Founded
2017
Employees
540

Today's Snapshot

AI-generated

BEAM closed 1.7% higher at 21.01, outperforming a weaker sector. Trading was busier than usual, with volume roughly twice its usual level. Beam Therapeutics advanced BEAM-302, a gene-editing treatment, toward late-stage testing.

Trading Volume

Above 10d avg 2.7M

4.8M

vs S&P 500 Today

Outperforming Market

+2.00%

Updated: November 18, 2026 at 21:25 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
BEAM displays a clear bearish bias as multiple measures align with selling pressure. Momentum oscillators are weak with a low RSI, strongly negative CCI and a negative MACD, and the stock trades well below its short, medium and long-term moving averages, signaling broad downside alignment. Trend strength is muted with a low ADX, but volatility is elevated and ATR near 1.72 reflects larger price swings, while OBV is negative indicating distribution. Technical takeaway: Sell — pervasive weakness across momentum and moving averages with elevated volatility underpins the bearish stance.
All signals
  • EMA (5 indicators)$23.26 - $27.00
    Sell
  • RSI (14)36.17
    Neutral
  • Stochastic %K (14, 3, 3)3.34
    Buy
  • MACD Level (12, 26)-0.96
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.